TransCode Therapeutics, Inc.(RNAZ)Earnings, Financials & Key RatiosTransCode Therapeutics, Inc. (RNAZ) stock price & volume — 10-year historical chart
Investment Thesis • Updated 2026Q1
the company's reliance on continuous capital consumption to fund operations, highlighted by a $17.8 million net loss in 2026Q1, presents an unsustainable risk profile for long-term investors.
TransCode Therapeutics, Inc. (RNAZ) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
TransCode Therapeutics, Inc. (RNAZ) EPS & revenue vs analyst estimates — last 4 quarters
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 15, 2026 | $21.28 | — |
| Q2 2026 | Apr 15, 2026 | $16.42vs $10.08-62.9% | — |
| Q4 2025 | Nov 14, 2025 | $5.49vs $9.24+40.6% | — |
| Q3 2025 | Aug 14, 2025 | $4.94vs $8.68+43.1% | — |
Recent stock market news and headlines for TransCode Therapeutics, Inc. (RNAZ)
TransCode Therapeutics, Inc. (RNAZ) Discusses Strategic, Scientific, and Clinical Updates With Focus on TTX-MC138 Phase 2a Trial in Colorectal Cancer Prepared Remarks Transcript
Key metrics vs top competitors for TransCode Therapeutics, Inc. (RNAZ)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $8.44 | $8.02M | -0.16 | — | — | -833.53% | — | |
| $86.97 | $12.25B | -7128.69 | 23258.15% | -48.38% | -55.09% | — | |
| $17.43 | $1.96B | -4.57 | 16.92% | -597.04% | -57.27% | — | |
| $19.79 | $2.09B | -2.78 | 15.58% | 2.98% | 4.89% | — | |
| $79.77 | $31.64B | -10.99 | -39.23% | -143.55% | -36.73% | — | |
| $86.33 | $14.27B | -36.27 | 33.87% | -30.87% | -58.57% | — |
TransCode Therapeutics, Inc. (RNAZ) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
TransCode Therapeutics, Inc. (RNAZ) SEC filings — annual & quarterly reports (10-K, 10-Q)
May 22, 2026·SEC
Apr 7, 2026·SEC
Mar 3, 2026·SEC
Get notified when RNAZ posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
TransCode Therapeutics, Inc. (RNAZ) stock FAQ — growth, dividends, profitability & financials explained
TransCode Therapeutics, Inc. (RNAZ) reported a net loss of $40.4M for fiscal year 2025.
TransCode Therapeutics, Inc. (RNAZ) has a return on equity (ROE) of -833.5%. Negative ROE indicates the company is unprofitable.
TransCode Therapeutics, Inc. (RNAZ) had negative free cash flow of $4.99B in fiscal year 2025, likely due to heavy capital investments.
